<DOC>
	<DOCNO>NCT02477826</DOCNO>
	<brief_summary>The purpose study show nivolumab , nivolumab plus ipilimumab , nivolumab plus platinum-doublet chemotherapy improve progression free survival and/or overall survival compare chemotherapy subject advance lung cancer</brief_summary>
	<brief_title>A Trial Nivolumab , Nivolumab Plus Ipilimumab , Nivolumab Plus Platinum-doublet Chemotherapy , Compared Platinum Doublet Chemotherapy Patients With Stage IV Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Subjects histologically confirm Stage IV recurrent NSCLC squamous nonsquamous histology , prior systemic anticancer therapy Subjects must program deathligand 1 ( PD L1 ) immunohistochemical ( IHC ) testing , result , performed central lab Screening period Eastern Cooperative Oncology Group ( ECOG ) Performance Status â‰¤ 1 Measurable disease CT MRI per response evaluation criterion solid tumor version 1.1 ( RECIST 1.1 ) criterion Subjects untreated Central nervous system ( CNS ) metastases excluded Subjects active , know suspected autoimmune disease exclude Any positive test hepatitis B virus hepatitis C virus human immunodeficiency virus ( HIV ) indicate acute chronic infection Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>